Acute Megakaryoblastic Leukemia Harboring a Subclone Expressing BCR-ABL1 Fusion Gene Product

Acute myeloid leukemia (AML) with BCR-ABL1, also termed Philadelphia chromosome-positive AML (Ph+ AML), is a rare leukemia subtype classified by the World Health Organization in 2016. The characteristics of Ph+ AML have not been fully identified yet. We herein report a patient with Ph+ AML who pheno...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2021/11/15, Vol.60(22), pp.3609-3614
Main Authors: Kashima, Emiko, Nakano, Eri, Watanabe, Yasuyuki, Imai, Hiroshi, Oka, Koji, Kageyama, Shinichi, Tanaka, Isao
Format: Article
Language:English
Subjects:
acute megakaryoblastic leukemia
Acute myeloid leukemia
BCR-ABL protein
BCR-ABL1 fusion gene
BCR-ABL1 gene
Case Report
Fusion protein
Fusion Proteins, bcr-abl - genetics
Humans
Internal medicine
Leukemia
Leukemia, Megakaryoblastic, Acute - genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Myeloid leukemia
Ph+ AML
Philadelphia chromosome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute myeloid leukemia (AML) with BCR-ABL1, also termed Philadelphia chromosome-positive AML (Ph+ AML), is a rare leukemia subtype classified by the World Health Organization in 2016. The characteristics of Ph+ AML have not been fully identified yet. We herein report a patient with Ph+ AML who phenotypically exhibited megakaryoblastic characteristics, FAB:M7 and harbored a subclone expressing BCR-ABL1 gene fusion products. This case suggests that BCR-ABL1 was acquired as a subclone due to a secondary event that might have occurred late during leukemia evolution. Our findings may aid in deciphering the mechanism underlying Ph+ AML development in future studies.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.7335-21